Chalante uses a range of modern biological and chemical technologies to deliver novel, effective and safe products to address animal health market needs


Population growth and global improvements in standards of living mean that demand for high-quality protein derived from food animals is increasing and more productivity must be gained from limited land. Innovations in food animal medicine are needed, as the current agents used to protect livestock are losing effectiveness due to emergence of new parasites and pests developing resistance.

Globally, the number of pet owners is increasing, as companion animals become more important in people's lives. 'Millennials' (those in the 18- to 34-year-old age group) have the highest likelihood of owning a pet. Members of this customer segment care about their pet’s health, comfort and wellbeing and are proponents of healthier foods and more natural pet treatments. Chalante’s focus is a development of novel treatments with natural product-inspired synthetic capabilities that are able to prevent resistant dog heartworm infections.


Chalante is focused on developing proprietary resistance breaking parasiticides and cost-effective processes to manufacture them for companion animals and livestock. Our parasiticides have a defined mode of action that is distinct from marketed products to which resistance has developed over the decades since their launch. We aim for products with novel mechanisms of action and excellent safety profiles. Chalante’s programs are designed to meet significant and valuable unmet needs in animal health.


Chalante’s focus on animal health pharmaceuticals have numerous advantages over the human pharmaceutical development. Human therapeutics are tested in non-human model species before human patients, whereas new animal health drug candidates can be tested directly in the target species. This reduces overall development time and clinical risk of entering into regulated studies, as they can be based upon earlier smaller scale studies using the same species, with the same physiology and a higher expectation to behave in a predictable way. Further, it takes about 5-6 years to progress a development candidate to a new drug and costs ten times less. Despite the smaller end markets for animal health products, with a combination of low risk of failure, quicker and cheaper routes to market and less competition from other biotechnology companies, animal health products represent an investment opportunity potentially as attractive as human health.

parallax background